1 / 73

ESC Guidelines 2010 on the management of Atrial Fibrillation

ESC Guidelines 2010 on the management of Atrial Fibrillation. European Heart Journal 2010. European Heart Rhythm Association (EHRA); Endorsed by the European Association for Cardio-Thoracic Surgery (EACTS). European Heart Journal (2010) 31, 2369-2429. Classes of recommendations.

chad
Download Presentation

ESC Guidelines 2010 on the management of Atrial Fibrillation

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. ESC Guidelines 2010 on the management ofAtrial Fibrillation European Heart Journal 2010 European Heart Rhythm Association (EHRA);Endorsed by the European Association for Cardio-Thoracic Surgery (EACTS) European Heart Journal (2010) 31, 2369-2429

  2. Classes of recommendations

  3. Levels of evidence

  4. Clinical Events (outcomes) affected by AF

  5. Conditions predisposing to, or encouraging progression of AF

  6. Types of Atrial Fibrillation

  7. Clinical evaluation

  8. Structural abnormalities associated with AF

  9. EHRA score of AF-related symptoms AF = atrial fibrillation; EHRA = European Heart Rhythm Association

  10. Natural time course of AF AF = atrial fibrillation

  11. Diagnosis and initial management of AF aClass of recommendation. bLevel of evidence. AF = atrial fibrillation; ECG = electrocardiogram; EHRA = European Heart Rhythm Association.

  12. Diagnosis and initial management of AF aClass of recommendation. bLevel of evidence. AF = atrial fibrillation; ECG = electrocardiogram.

  13. Diagnosis and initial management of AF aClass of recommendation. bLevel of evidence. AF = atrial fibrillation; ECG = electrocardiogram.

  14. The management cascade for patients with AF ACEI = angiotensin-converting enzyme inhibitor; AF = atrial fibrillation; ARB = angiotensin receptor blocker;PUFA = polyunsaturated fatty acid; TE = thrombo-embolism.

  15. CHADS2 score and stroke rate *The adjusted stroke rate was derived from the multivariable analysis assuming no aspirin usage; these stroke rates arebased on data from a cohort of hospitalised AF patients, published in 2001, with low numbers in those with a CHADS2 scoreof 5 and 6 to allow an accurate judgement of the risk in these patients. Given that stroke rates are declining overall, actualstroke rates in contemporary non-hospitalised cohorts may also vary from these estimates. Adapted from Gage BF et al. AF = atrial fibrillation; CHADS2 = cardiac failure, hypertension, age, diabetes, stroke (doubled).

  16. Risk factors for stroke andthrombo-embolism in non-valvular AF AF= atrial fibrillation; EF = ejection fraction (as documented by echocardiography, radionuclide ventriculography, cardiaccatheterization, cardiac magnetic resonance imaging, etc.); LV = left ventricular; TIA = transient ischaemic attack.

  17. Risk factor-based point-based scoring system - CHA2DS2-VASc *Prior myocardial infarction, peripheral artery disease, aortic plaque. Actual rates of stroke in contemporarycohorts may vary from these estimates.

  18. Adjusted stroke rate according to CHA2DS2-VASc score

  19. Use of oral anticoagulation forstroke prevention in AF AF = atrial fibrillation; OAC = oral anticoagulant; TIA = transient ischaemic attack.

  20. Approach to thromboprophylaxis in AF AF = atrial fibrillation; CHA2DS2-VASc = cardiac failure, hypertension, age ≥ 75 (doubled), diabetes, stroke (doubled)-vascular disease, age 65–74 and sex category (female); INR = international normalized ratio; OAC = oral anticoagulation, such as a vitamin K antagonist (VKA) adjusted to an intensity range of INR 2.0–3.0 (target 2.5).

  21. The HAS-BLED bleeding risk score *Hypertension is defined as systolic blood pressure > 160 mmHg. INR = international normalized ratio.

  22. Cardioversion, TOE and anticoagulation AF = atrial fibrillation; DCC = direct currentcardioversion; LA = left atrium; LAA = left atrial appendage; OAC = oral anticoagulant;SR= sinus rhythm; TOE= transoesophagealechocardiography.

  23. Prevention of thromboembolism in AF

  24. Prevention of thromboembolism in AF

  25. Prevention of thromboembolism in AF aClass of recommendation. bLevel of evidence. AF = atrial fibrillation; CHADS2 = cardiac failure, hypertension, age, diabetes, stroke (doubled);INR = international normalized ratio; LMWH = low molecular weight heparin; OAC = oral anticoagulant; TIA = transient ischaemic attack; VKA = vitamin K antagonist.

  26. Drugs and doses for pharmacological conversion of (recent-onset) AF ACS = acute coronary syndrome; AF = atrial fibrillation; DCC = direct current cardioversion; i.v. = intravenous;N/A = not applicable; NYHA, New York Heart Association; p.o. = per os; QRS = QRS duration; QT = QT interval;T-U = abnormal repolarization (T-U) waves.

  27. DCC and pharmacological conversion recent-onset AF AF = atrial fibrillation; i.v. = intravenous.

  28. Pharmacological cardioversion of AF aClass of recommendation. bLevel of evidence. AF = atrial fibrillation; LoE = level of evidence; i.v. = intravenous.

  29. DC cardioversion for AF aClass of recommendation. bLevel of evidence. AF = atrial fibrillation; DCC = direct current cardioversion.

  30. General Management of the AF Patient

  31. Choice of rate and rhythm control strategies

  32. Rate and rhythm control of AF aClass of recommendation. bLevel of evidence. AF = atrial fibrillation; EHRA = European Heart Rhythm Association.

  33. Optimal level of heart rate control

  34. Rate control of atrial fibrillation The choice of drugs depends on life style and underlying disease

  35. Drugs for rate control ER = extended release formulations; N/A = not applicable. ‡Only in patients with non-permanent atrial fibrillation.

  36. Acute rate control in AF aClass of recommendation. bLevel of evidence. AF = atrial fibrillation; i.v. = intravenous.

  37. Long-term rate control in AF aClass of recommendation. bLevel of evidence. AF = atrial fibrillation; bmp = beats per minute; LV = left ventricular; NYHA = New York Heart Association.

  38. Long-term rate control in AF aClass of recommendation. bLevel of evidence.AF = atrial fibrillation; bmp = beats per minute; LV = left ventricular; NYHA = New York Heart Association.

  39. AV node ablation in AF patients aClass of recommendation. bLevel of evidence. AF = atrial fibrillation; AV = atrioventricular; CRT = cardiac resynchronization therapy; LV = left ventricular;LVEF = left ventricular ejection fraction; NYHA = New York Heart Association.

  40. AV node ablation in AF patients aClass of recommendation. bLevel of evidence. AF = atrial fibrillation; AV = atrioventricular; CRT = cardiac resynchronizationtherapy; LV = left ventricular; LVEF = left ventricular ejection fraction; NYHA = New York Heart Association.

  41. Choice of pacemakers afterAV node ablation aClass of recommendation. bLevel of evidence. AF = atrial fibrillation; AV = atrioventricular; CRT = cardiac resynchronization therapy; LV = left ventricular;LVEF = left ventricular ejection fraction; NYHA = New York Heart Association.

  42. Principles of antiarrhythmic drugtherapy to maintain sinus rhythm Treatment is motivated by attempts to reduce AF-relatedsymptoms. Efficacy of antiarrhythmic drugs to maintain sinus rhythm is modest. Clinically successful antiarrhythmic drug therapy may reduce ratherthan eliminate recurrence of AF. If one antiarrhythmic drug ‘fails’ a clinically acceptable responsemay be achieved with another agent. Drug-induced proarrhythmia or extra-cardiac side-effects arefrequent. Safety rather than efficacy considerations should primarily guidethe choice of antiarrhythmic agent.

  43. Suggested doses and main caveats forcommonly used antiarrhythmic drugs AF = atrial fibrillation; AV = atrioventricular; bpm = beats per minute; CYP = cytochrome P; ECG = electrocardiogram;LV = left ventricular; NYHA = New York Heart Association.

  44. Suggested doses and main caveats for commonly used antiarrhythmic drugs(Contd) AF = atrial fibrillation; AV = atrioventricular; bpm = beats per minute; CYP = cytochrome P; ECG = electrocardiogram;LV = left ventricular; NYHA = New York Heart Association.

  45. Suggested doses and main caveats for commonly used antiarrhythmic drugs(Contd) AF = atrial fibrillation; AV = atrioventricular; bpm = beats per minute; CYP = cytochrome P; ECG = electrocardiogram;LV = left ventricular; NYHA = New York Heart Association.

  46. Choice of antiarrhythmic for the patientwith no or minimal structural heart disease

  47. Choice of antiarrhythmic drugaccording to underlying pathology ACEI = angiotensin-converting enzyme inhibitor; ARB = angiotensin receptor blocker; CAD = coronary artery disease; CHF = congestive heart failure;HT = hypertension; LVH = left ventricular hypertrophy; NYHA = New York Heart Association; unstable = cardiac decompensation within the prior4 weeks. Antiarrhythmic agents are listed in alphabetical order within each treatment box. ? = evidence for ‘upstream’ therapy for prevention of atrialremodelling still remains controversial.

  48. Choice of an antiarrhythmic drugfor AF control aClass of recommendation. bLevel of evidence.AF = atrial fibrillation; AV = atrioventricular; LoE = level of evidence; NYHA = New York Heart Association.

  49. Choice of an antiarrhythmic drugfor AF control aClass of recommendation. bLevel of evidence.AF = atrial fibrillation; AV = atrioventricular; LoE = level of evidence; NYHA = New York Heart Association.

More Related